Is Homoarginine a Protective Cardiovascular Risk Factor?

ES Karetnikova, N Jarzebska, AG Markov, N Weiss, SR. Lentz, RN Rodionov

Research output

4 Citations (Scopus)

Abstract

A series of recent epidemiological studies have implicated the endogenous nonproteinogenic amino acid l-homoarginine as a novel candidate cardiovascular risk factor. The association between homoarginine levels and the risk of adverse cardiovascular outcomes is inverse (ie, high cardiovascular risk is predicted by low rather than high homoarginine levels), which makes it plausible to normalize systemic homoarginine levels via oral supplementation. The emergence of homoarginine as a potentially treatable protective cardiovascular risk factor has generated a wave of hope in the field of cardiovascular prevention. Herein, we review the biochemistry, physiology, and metabolism of homoarginine, summarize the strengths and weaknesses of the epidemiological evidence linking homoarginine to cardiovascular disease and its potential protective cardiovascular effects, and identify priorities for future research needed to define the clinical utility of homoarginine as a prognostic factor and therapeutic target in cardiovascular disease.

Original languageEnglish
Article numberQ1
Pages (from-to)869-875
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume39
Issue number5
DOIs
Publication statusPublished - May 2019

Fingerprint

Homoarginine
Cardiovascular Diseases
Biochemistry
Epidemiologic Studies
Amino Acids

Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Karetnikova, ES ; Jarzebska, N ; Markov, AG ; Weiss, N ; Lentz, SR. ; Rodionov, RN. / Is Homoarginine a Protective Cardiovascular Risk Factor?. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2019 ; Vol. 39, No. 5. pp. 869-875.
@article{c228aa45dbdd41aea3ff9cc98974a558,
title = "Is Homoarginine a Protective Cardiovascular Risk Factor?",
abstract = "A series of recent epidemiological studies have implicated the endogenous nonproteinogenic amino acid l-homoarginine as a novel candidate cardiovascular risk factor. The association between homoarginine levels and the risk of adverse cardiovascular outcomes is inverse (ie, high cardiovascular risk is predicted by low rather than high homoarginine levels), which makes it plausible to normalize systemic homoarginine levels via oral supplementation. The emergence of homoarginine as a potentially treatable protective cardiovascular risk factor has generated a wave of hope in the field of cardiovascular prevention. Herein, we review the biochemistry, physiology, and metabolism of homoarginine, summarize the strengths and weaknesses of the epidemiological evidence linking homoarginine to cardiovascular disease and its potential protective cardiovascular effects, and identify priorities for future research needed to define the clinical utility of homoarginine as a prognostic factor and therapeutic target in cardiovascular disease.",
keywords = "cardiovascular disease, epidemiological studies, homoarginine, risk factor, single nucleotide polymorphism, MORTALITY, SERUM ALKALINE-PHOSPHATASE, POPULATION, MYOCARDIAL-INFARCTION, ASYMMETRIC DIMETHYLARGININE, ORAL L-ARGININE, SUBSTRATE-SPECIFICITY, PLASMA-CONCENTRATIONS, DISEASE, NITRIC-OXIDE",
author = "ES Karetnikova and N Jarzebska and AG Markov and N Weiss and SR. Lentz and RN Rodionov",
year = "2019",
month = "5",
doi = "10.1161/ATVBAHA.118.312218",
language = "English",
volume = "39",
pages = "869--875",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Is Homoarginine a Protective Cardiovascular Risk Factor? / Karetnikova, ES; Jarzebska, N; Markov, AG; Weiss, N; Lentz, SR.; Rodionov, RN.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 39, No. 5, Q1, 05.2019, p. 869-875.

Research output

TY - JOUR

T1 - Is Homoarginine a Protective Cardiovascular Risk Factor?

AU - Karetnikova, ES

AU - Jarzebska, N

AU - Markov, AG

AU - Weiss, N

AU - Lentz, SR.

AU - Rodionov, RN

PY - 2019/5

Y1 - 2019/5

N2 - A series of recent epidemiological studies have implicated the endogenous nonproteinogenic amino acid l-homoarginine as a novel candidate cardiovascular risk factor. The association between homoarginine levels and the risk of adverse cardiovascular outcomes is inverse (ie, high cardiovascular risk is predicted by low rather than high homoarginine levels), which makes it plausible to normalize systemic homoarginine levels via oral supplementation. The emergence of homoarginine as a potentially treatable protective cardiovascular risk factor has generated a wave of hope in the field of cardiovascular prevention. Herein, we review the biochemistry, physiology, and metabolism of homoarginine, summarize the strengths and weaknesses of the epidemiological evidence linking homoarginine to cardiovascular disease and its potential protective cardiovascular effects, and identify priorities for future research needed to define the clinical utility of homoarginine as a prognostic factor and therapeutic target in cardiovascular disease.

AB - A series of recent epidemiological studies have implicated the endogenous nonproteinogenic amino acid l-homoarginine as a novel candidate cardiovascular risk factor. The association between homoarginine levels and the risk of adverse cardiovascular outcomes is inverse (ie, high cardiovascular risk is predicted by low rather than high homoarginine levels), which makes it plausible to normalize systemic homoarginine levels via oral supplementation. The emergence of homoarginine as a potentially treatable protective cardiovascular risk factor has generated a wave of hope in the field of cardiovascular prevention. Herein, we review the biochemistry, physiology, and metabolism of homoarginine, summarize the strengths and weaknesses of the epidemiological evidence linking homoarginine to cardiovascular disease and its potential protective cardiovascular effects, and identify priorities for future research needed to define the clinical utility of homoarginine as a prognostic factor and therapeutic target in cardiovascular disease.

KW - cardiovascular disease

KW - epidemiological studies

KW - homoarginine

KW - risk factor

KW - single nucleotide polymorphism

KW - MORTALITY

KW - SERUM ALKALINE-PHOSPHATASE

KW - POPULATION

KW - MYOCARDIAL-INFARCTION

KW - ASYMMETRIC DIMETHYLARGININE

KW - ORAL L-ARGININE

KW - SUBSTRATE-SPECIFICITY

KW - PLASMA-CONCENTRATIONS

KW - DISEASE

KW - NITRIC-OXIDE

UR - http://www.scopus.com/inward/record.url?scp=85065324114&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/homoarginine-protective-cardiovascular-risk-factor

U2 - 10.1161/ATVBAHA.118.312218

DO - 10.1161/ATVBAHA.118.312218

M3 - Review article

VL - 39

SP - 869

EP - 875

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 5

M1 - Q1

ER -